Supplement to May–June 2015 Issue: CNS Summit 2014 Abstracts of Poster Presentations

Conclusion: Due to limitations, these results may not be applicable to the general population. The present study provides evidence that LAIs stabilize or improve outcome measures while reducing hospitalization and overall costs. LAIs should be used as first-line agents and prophylactically rather than as a last resort. Ultimately, the decision to use LAIs should be driven by careful consideration of potential side effects and likelihood of adherence to therapy. Funding/disclosures: The authors have no conflicts of interest relevant to the study. The study was funded by GPI Clinical Research. Key words: Schizophrenia, cost-effectiveness   Biomarker profiling of NSI-189 phosphate, a neurogenic compound, in patients with major depressive disorder (MDD) during a Phase Ib randomized, double-blind, placebo-controlled trial Presenters: 1Bilello JA, 1Feng X, 1Thurmond LM, 2Gertsik L, 3English BA, 3Ereshefsky L, 4Fava M, 4Hoeppner B, 4Flynn M, 4Mischoulon D, 4Kinrys G, 4Freeman M, 5Johe K Affiliations: 1Ridge Diagnostics; 2California Clinical Trials Medical Group; 3PAREXEL International; 4Harvard Medical School, Clinical Trials Network & Institute (CTNI), Massachusetts General Hospital; 5Neuralstem, Inc. Background: Few biomarkers of antidepressant treatment response are in current use as an adjunct to clinical response measurements made using subjective clinical assessment tools. Our aim was to explore biomarkers on the MDDScore™ test panel (Ridge Diagnostics) for the abil...
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: Tags: Drug Development Genetics Neurology Psychiatry Psychopharmacology Supplements Trial Methodology 2014 CNS Summit poster abstracts Source Type: research